Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2003
11/05/2003CN1126552C Marine biological selenium products and preparing process thereof
11/05/2003CN1126547C Lentinan holosida freeze-dried powder injecta and its preparation
11/05/2003CN1126539C Application of tanshinone in medicine preparation for treating tumor
11/04/2003US6642410 Useful as antiproliferative agents, including, for example, anticancer agents
11/04/2003US6642386 N-(4-carbamimidoyl-phenyl)-glycine derivatives
11/04/2003US6642368 Programmed cell death and caspase-12
11/04/2003US6642367 Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
11/04/2003US6642362 Genes coding proteins for early liver development and their use in diagnosing and treating liver disease
11/04/2003US6642271 Potentiating compounds
11/04/2003US6642255 Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide
11/04/2003US6642252 Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer.
11/04/2003US6642251 Antitumor, 2-indolinone derivatives
11/04/2003US6642248 Antitumor, anticancer agent
11/04/2003US6642239 Dipeptide nitrile cathepsin K inhibitors
11/04/2003US6642232 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
11/04/2003US6642231 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
11/04/2003US6642227 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
11/04/2003US6642218 (5Z,7E,22E)-(1S,3R,24R)-25-(5-Propyloxazol-2-yl)-26,27-cyclo -9,10-secocholesta-5,7,10(19), 22-tetraene-1,3,24-triol for treatment of diseases characterized by hyperproliferation and deficient cell differentiation
11/04/2003US6642214 Oligomer consisting of two cyclodextrin molecules joined by bifunctional spacer, optionally having affinity group which interacts with molecular target structure; physical inclusion complex formed with drug reduces side effects
11/04/2003US6642212 Health supplement comprising naturally occurring phytoestrogen selected from any two or more of genistein, daidzein and/or their glycosides
11/04/2003US6642206 Monocyclic L-nucleosides, analogs and uses thereof
11/04/2003US6642010 Identifying, monitoring, and treating women for breast precancer or cancer
11/04/2003US6642008 Assays and therapies for latent viral infection
11/04/2003US6641833 Extended release of paclitaxel by intraperitoneal administration
11/04/2003US6641820 Treating a bone tumor, in particular pain associated with bone tumor, by administration to a patient of a therapeutically effective amount of an agent are disclosed. The agent may include a clostridial neurotoxin component attached to target
11/04/2003US6641817 Herpes virus vectors for dendritic cells
11/04/2003US6641816 Use of poxviruses as enhancer of specific immunity
11/04/2003US6641798 Tumor-targeted optical contrast agents
11/04/2003CA2257322C Thiazole derivatives
11/04/2003CA2094773C 2,4-dioxoimidazolidine derivatives
11/04/2003CA2091001C Baccatine iii derivatives
10/2003
10/31/2003CA2444598A1 Compositions useful as inhibitors of gsk-3
10/30/2003WO2003089667A1 Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
10/30/2003WO2003089624A2 Fc receptor homolog, reagents, and uses thereof
10/30/2003WO2003089608A2 Drg11-responsive (dragon) gene family
10/30/2003WO2003089596A2 Novel prostate tumor-specific promoter
10/30/2003WO2003089593A2 Adjuvant enhanced immunotherapy
10/30/2003WO2003089583A2 Tissue specific genes and gene clusters
10/30/2003WO2003089573A2 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
10/30/2003WO2003089569A2 Use of il-19, il-22 and il-24 to treat hematopoietic disorders
10/30/2003WO2003089462A2 Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
10/30/2003WO2003089450A2 Fusion polypeptides and methods for inhibiting microbial adhesion
10/30/2003WO2003089449A2 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity
10/30/2003WO2003089439A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof
10/30/2003WO2003089434A2 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF
10/30/2003WO2003089430A1 Thioxanthine derivatives as myeloperoxidase inhibitors
10/30/2003WO2003089428A1 Tricyclic thrombin receptor antagonists
10/30/2003WO2003089423A2 Novel flavanoids and chalcones as chemotherapeutic, chemopreventive, and antiangiogenic agents
10/30/2003WO2003089415A1 Amonafide salts
10/30/2003WO2003089413A1 Pharmacia corporation
10/30/2003WO2003089410A1 Phenylalanine derivative
10/30/2003WO2003089046A1 Method of treating biological materials with translating electrical fields and electrode polarity reversal
10/30/2003WO2003089010A1 Glycodendrimers having biological activity
10/30/2003WO2003089006A1 Combination of an agent that attenuates topoisomerase 1 activity and an agent that inhibits heat shock protein 90 for use in chemotherapy
10/30/2003WO2003089001A1 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
10/30/2003WO2003088998A1 Antibody combination useful for tumor therapy
10/30/2003WO2003088996A2 Lewis y epitope modified polypeptide, or mucin fusion polypetide, tumor vaccines
10/30/2003WO2003088995A2 Mucin fusion polypeptide vaccines, compositions and methods of use thereof
10/30/2003WO2003088979A2 Oligonucleotides from sequences coding for the surface component of envelope proteins of primate t-cell leukaemia/lymphoma viruses (ptlv) and uses thereof
10/30/2003WO2003088977A1 (20S)-1α-HYDROXY-2α-METHYL AND 2β-METHYL-19-NOR-VITAMIN D3 AND THEIR USES
10/30/2003WO2003088972A1 Novel compounds
10/30/2003WO2003088971A1 Combination therapy for the treatment of cancer
10/30/2003WO2003088970A2 Modulators of hedgehog signaling pathways, compositions and uses related thereto
10/30/2003WO2003088969A1 Anhydrovinblastine for the treatment of cancer
10/30/2003WO2003088964A1 Use of cyclopamine in the treatment of psoriasis and other skin disorders
10/30/2003WO2003088960A1 Anti-tumour agents
10/30/2003WO2003088954A1 Combination therapy for the treatment of cancer
10/30/2003WO2003088927A2 Novel curcumin analogues and uses thereof
10/30/2003WO2003088920A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics
10/30/2003WO2003088915A2 Novel sodium channel blockers
10/30/2003WO2003088903A2 Compounds, compositions, and methods
10/30/2003WO2003088900A2 Solid forms of salts with tyrosine kinase activity
10/30/2003WO2003088898A2 Compositions and methods for the diagnosis and treatment of tumor
10/30/2003WO2003073841A3 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
10/30/2003WO2003066579A3 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
10/30/2003WO2003063796A3 Heterocyclic arylsulfonamidobenzylic compounds
10/30/2003WO2003057837A8 Methods for using anti-muc18 antibodies
10/30/2003WO2003055527A3 Immunoconjugates useful for treatment of tumours
10/30/2003WO2003053365A3 Syn3 compositions and methods
10/30/2003WO2003052095A3 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
10/30/2003WO2003051388A3 Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
10/30/2003WO2003051277A3 Novel compounds
10/30/2003WO2003051274A3 Benzodiazepine derivatives, preparation thereof and use thereof
10/30/2003WO2003047697A3 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
10/30/2003WO2003047633A3 Treatment of angiogenesis disorders using targeted nanoparticles
10/30/2003WO2003047508A3 Paclitaxel solvates
10/30/2003WO2003045404A3 Treatment and diagnosis of diseases associated with adverse levels of zinc, cadmium and calcium
10/30/2003WO2003039545A3 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
10/30/2003WO2003034997A3 Modulators of phosphoinositide 3-kinase
10/30/2003WO2003034903A3 Psma antibodies and protein multimers
10/30/2003WO2003032921A3 Treatment of neurodegenerative diseases and cancer of the brain
10/30/2003WO2003032899A3 Methods and materials for targeting and affecting selected cells
10/30/2003WO2003031568A3 Intracellular signaling molecules
10/30/2003WO2003028527A3 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
10/30/2003WO2003027143A3 Gene and protein relating to hepatocellular carcinoma
10/30/2003WO2003025199A3 Mid 4460, a human tyrosine phosphatase family member and uses therefor
10/30/2003WO2003024480A3 In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
10/30/2003WO2003020320A3 Nanoparticles comprising biologically active tnf which is immobilised on the same
10/30/2003WO2003020309A3 Compound
10/30/2003WO2003016549A3 Nucleic-acid associated proteins
1 ... 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 ... 2211